• Enthera, the first spin-off of BiovelocITA, completed €4 million seed-expansion financing 24 July 2018

    Enthera, an innovative Italian start-up dedicated to the research and development of innovative therapeutics to treat Type 1 Diabetes and gastrointestinal diseases, received an investment of €4 million led by Sofinnova along with the JDRF T1D Fund (the venture capital fund of the authoritative US JDRF Foundation dedicated to promoting research on Type 1 Diabetes), the accelerator BiovelocITA and its shareholders.

    Read more

  • Enthera and Trianni Announce Licensing Agreement 22 March 2018

    Trianni, Inc. (“TRIANNI”) and Enthera, S.r.L. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.

    Read more

  • BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer 23 November 2016

    Two research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners. The collaborations were sealed with Enthera, a start-up that will develop therapies to treat diabetes, and a research project from the Milanese IFOM (the FIRC Institute of Molecular Oncology) for the development of anti-cancer drugs.

    Read more